



Evidence Modernization in Oncology: A Regulatory Perspective

Donna R. Rivera, PharmD., MSc.
Associate Director for Pharmacoepidemiology
Oncology Center of Excellence, US FDA

Cancer Drug Development Forum

FDA Oncology RWE Program Overview

Established 2020



Program Statement

Collaboratively advance the appropriate use of real-world evidence in oncology product development to facilitate patient-centered regulatory decision-making.

Oncology RWE Program

Focus Areas

Regulatory Review

Regulatory Science Research

Collaborations & Outreach

Education & Engagement



FDA Oncology Real World Evidence Program

Regulatory Review

Completed ~200 Oncology RWE consults across FDA centers

Regulatory consults for Oncology RWD increasing over time

Drugs (CDER)

Devices (CDRH)

Biologics (CBER)

TEAM *F_oRWD*

Translational Evaluation and Assessment of Methods to Facilitate use of Oncology RWD



Regulatory Science Research

Initial Program Strategic Goals

Enhance Source Data


- ALLIANCE, mCODE
- UMGCCC-Medicare Database
- OU AI/AN Database
- ASH Collaborative

Standardize Submissions

- Oncology QCARD (Reagan Udall Foundation)

Develop Real World Endpoints

- rwResponse Study (Friends of Cancer Research)
- rwLugano Criteria (Cardinal Health)



Oncology QCARD
Oncology Quality, Characterization, and Assessment of Real-World Data

Common Data Elements for Early Phases of Oncology Studies Using RWD	Medical Use
• Patient Demographics	• Patient ID
• Patient Location	• Date of Birth
• Patient Race	• Sex
• Patient Ethnicity	• Date of Admission
• Patient Insurance	• Date of Discharge
• Patient Referring Physician	• Date of Death
• Patient Referring Institution	• Date of Last Contact
• Patient Referring Specialty	• Date of Last Update
• Patient Referring Institution ID	• Date of Last Update
• Patient Referring Specialty ID	• Date of Last Update
• Patient Referring Institution Name	• Date of Last Update
• Patient Referring Specialty Name	• Date of Last Update
• Patient Referring Institution Address	• Date of Last Update
• Patient Referring Specialty Address	• Date of Last Update
• Patient Referring Institution City	• Date of Last Update
• Patient Referring Specialty City	• Date of Last Update
• Patient Referring Institution State	• Date of Last Update
• Patient Referring Specialty State	• Date of Last Update
• Patient Referring Institution Zip	• Date of Last Update
• Patient Referring Specialty Zip	• Date of Last Update
• Patient Referring Institution Country	• Date of Last Update
• Patient Referring Specialty Country	• Date of Last Update
• Patient Referring Institution Phone	• Date of Last Update
• Patient Referring Specialty Phone	• Date of Last Update
• Patient Referring Institution Fax	• Date of Last Update
• Patient Referring Specialty Fax	• Date of Last Update
• Patient Referring Institution Email	• Date of Last Update
• Patient Referring Specialty Email	• Date of Last Update
• Patient Referring Institution Website	• Date of Last Update
• Patient Referring Specialty Website	• Date of Last Update
• Patient Referring Institution Social Media	• Date of Last Update
• Patient Referring Specialty Social Media	• Date of Last Update
• Patient Referring Institution Logo	• Date of Last Update
• Patient Referring Specialty Logo	• Date of Last Update
• Patient Referring Institution Mission Statement	• Date of Last Update
• Patient Referring Specialty Mission Statement	• Date of Last Update
• Patient Referring Institution Values	• Date of Last Update
• Patient Referring Specialty Values	• Date of Last Update
• Patient Referring Institution Vision	• Date of Last Update
• Patient Referring Specialty Vision	• Date of Last Update
• Patient Referring Institution Strategic Plan	• Date of Last Update
• Patient Referring Specialty Strategic Plan	• Date of Last Update
• Patient Referring Institution Annual Report	• Date of Last Update
• Patient Referring Specialty Annual Report	• Date of Last Update
• Patient Referring Institution Financial Statements	• Date of Last Update
• Patient Referring Specialty Financial Statements	• Date of Last Update
• Patient Referring Institution Tax Returns	• Date of Last Update
• Patient Referring Specialty Tax Returns	• Date of Last Update
• Patient Referring Institution Audits	• Date of Last Update
• Patient Referring Specialty Audits	• Date of Last Update
• Patient Referring Institution Certifications	• Date of Last Update
• Patient Referring Specialty Certifications	• Date of Last Update
• Patient Referring Institution Licenses	• Date of Last Update
• Patient Referring Specialty Licenses	• Date of Last Update
• Patient Referring Institution Permits	• Date of Last Update
• Patient Referring Specialty Permits	• Date of Last Update
• Patient Referring Institution Insurance Policies	• Date of Last Update
• Patient Referring Specialty Insurance Policies	• Date of Last Update
• Patient Referring Institution Contracts	• Date of Last Update
• Patient Referring Specialty Contracts	• Date of Last Update
• Patient Referring Institution Agreements	• Date of Last Update
• Patient Referring Specialty Agreements	• Date of Last Update
• Patient Referring Institution Policies and Procedures	• Date of Last Update
• Patient Referring Specialty Policies and Procedures	• Date of Last Update
• Patient Referring Institution Standard Operating Procedures	• Date of Last Update
• Patient Referring Specialty Standard Operating Procedures	• Date of Last Update
• Patient Referring Institution Quality Improvement Plans	• Date of Last Update
• Patient Referring Specialty Quality Improvement Plans	• Date of Last Update
• Patient Referring Institution Risk Management Plans	• Date of Last Update
• Patient Referring Specialty Risk Management Plans	• Date of Last Update
• Patient Referring Institution Compliance Programs	• Date of Last Update
• Patient Referring Specialty Compliance Programs	• Date of Last Update
• Patient Referring Institution Ethics Committees	• Date of Last Update
• Patient Referring Specialty Ethics Committees	• Date of Last Update
• Patient Referring Institution Research Committees	• Date of Last Update
• Patient Referring Specialty Research Committees	• Date of Last Update
• Patient Referring Institution Institutional Review Boards	• Date of Last Update
• Patient Referring Specialty Institutional Review Boards	• Date of Last Update
• Patient Referring Institution Human Subjects Protection	• Date of Last Update
• Patient Referring Specialty Human Subjects Protection	• Date of Last Update
• Patient Referring Institution Data Privacy Policies	• Date of Last Update
• Patient Referring Specialty Data Privacy Policies	• Date of Last Update
• Patient Referring Institution Data Security Policies	• Date of Last Update
• Patient Referring Specialty Data Security Policies	• Date of Last Update
• Patient Referring Institution Data Retention Policies	• Date of Last Update
• Patient Referring Specialty Data Retention Policies	• Date of Last Update
• Patient Referring Institution Data Archiving Policies	• Date of Last Update
• Patient Referring Specialty Data Archiving Policies	• Date of Last Update
• Patient Referring Institution Data Backup Policies	• Date of Last Update
• Patient Referring Specialty Data Backup Policies	• Date of Last Update
• Patient Referring Institution Data Recovery Policies	• Date of Last Update
• Patient Referring Specialty Data Recovery Policies	• Date of Last Update
• Patient Referring Institution Data Migration Policies	• Date of Last Update
• Patient Referring Specialty Data Migration Policies	• Date of Last Update
• Patient Referring Institution Data Integration Policies	• Date of Last Update
• Patient Referring Specialty Data Integration Policies	• Date of Last Update
• Patient Referring Institution Data Interoperability Policies	• Date of Last Update
• Patient Referring Specialty Data Interoperability Policies	• Date of Last Update
• Patient Referring Institution Data Exchange Policies	• Date of Last Update
• Patient Referring Specialty Data Exchange Policies	• Date of Last Update
• Patient Referring Institution Data Sharing Policies	• Date of Last Update
• Patient Referring Specialty Data Sharing Policies	• Date of Last Update
• Patient Referring Institution Data Access Policies	• Date of Last Update
• Patient Referring Specialty Data Access Policies	• Date of Last Update
• Patient Referring Institution Data Ownership Policies	• Date of Last Update
• Patient Referring Specialty Data Ownership Policies	• Date of Last Update
• Patient Referring Institution Data Licensing Policies	• Date of Last Update
• Patient Referring Specialty Data Licensing Policies	• Date of Last Update
• Patient Referring Institution Data Attribution Policies	• Date of Last Update
• Patient Referring Specialty Data Attribution Policies	• Date of Last Update
• Patient Referring Institution Data Acknowledgment Policies	• Date of Last Update
• Patient Referring Specialty Data Acknowledgment Policies	• Date of Last Update
• Patient Referring Institution Data Disclaimer Policies	• Date of Last Update
• Patient Referring Specialty Data Disclaimer Policies	• Date of Last Update
• Patient Referring Institution Data Waiver Policies	• Date of Last Update
• Patient Referring Specialty Data Waiver Policies	• Date of Last Update
• Patient Referring Institution Data Release Policies	• Date of Last Update
• Patient Referring Specialty Data Release Policies	• Date of Last Update
• Patient Referring Institution Data Destruction Policies	• Date of Last Update
• Patient Referring Specialty Data Destruction Policies	• Date of Last Update
• Patient Referring Institution Data Archiving Policies	• Date of Last Update
• Patient Referring Specialty Data Archiving Policies	• Date of Last Update
• Patient Referring Institution Data Backup Policies	• Date of Last Update
• Patient Referring Specialty Data Backup Policies	• Date of Last Update
• Patient Referring Institution Data Recovery Policies	• Date of Last Update
• Patient Referring Specialty Data Recovery Policies	• Date of Last Update
• Patient Referring Institution Data Migration Policies	• Date of Last Update
• Patient Referring Specialty Data Migration Policies	• Date of Last Update
• Patient Referring Institution Data Integration Policies	• Date of Last Update
• Patient Referring Specialty Data Integration Policies	• Date of Last Update
• Patient Referring Institution Data Interoperability Policies	• Date of Last Update
• Patient Referring Specialty Data Interoperability Policies	• Date of Last Update
• Patient Referring Institution Data Exchange Policies	• Date of Last Update
• Patient Referring Specialty Data Exchange Policies	• Date of Last Update
• Patient Referring Institution Data Sharing Policies	• Date of Last Update
• Patient Referring Specialty Data Sharing Policies	• Date of Last Update
• Patient Referring Institution Data Access Policies	• Date of Last Update
• Patient Referring Specialty Data Access Policies	• Date of Last Update
• Patient Referring Institution Data Ownership Policies	• Date of Last Update
• Patient Referring Specialty Data Ownership Policies	• Date of Last Update
• Patient Referring Institution Data Licensing Policies	• Date of Last Update
• Patient Referring Specialty Data Licensing Policies	• Date of Last Update
• Patient Referring Institution Data Attribution Policies	• Date of Last Update
• Patient Referring Specialty Data Attribution Policies	• Date of Last Update
• Patient Referring Institution Data Acknowledgment Policies	• Date of Last Update
• Patient Referring Specialty Data Acknowledgment Policies	• Date of Last Update
• Patient Referring Institution Data Disclaimer Policies	• Date of Last Update
• Patient Referring Specialty Data Disclaimer Policies	• Date of Last Update
• Patient Referring Institution Data Waiver Policies	• Date of Last Update
• Patient Referring Specialty Data Waiver Policies	• Date of Last Update
• Patient Referring Institution Data Release Policies	• Date of Last Update
• Patient Referring Specialty Data Release Policies	• Date of Last Update
• Patient Referring Institution Data Destruction Policies	• Date of Last Update
• Patient Referring Specialty Data Destruction Policies	• Date of Last Update

Friends of Cancer Research Collaborative rwResponse Pilot

Established a unique multi-stakeholder research partnership:

- To develop a common protocol and statistical analysis plan for measuring re-response
- To initiate a pilot to assess the consistency of the measure in an aligned patient population across datasets

Pilot Objectives

1. Assess the availability and frequency of core data components for measuring re-response including:
 - Raw images
 - Image reports
 - Clinician assessment
2. Evaluate the consistency of a measure of re-response across data sources in the aligned patient population
 - re-response rate (rwRR)
 - re-duration of response (rwDOR)
 - Association between re-response and time-to-event endpoints



REGULATORY OVERVIEW

Recently Released FDA RWE Guidances



Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products

Draft Guidance for Industry, September 2021

Data Standards for Drug and Biological Product Submissions Containing Real-World Data

Draft Guidance for Industry, October 2021

**Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products
Guidance for Industry**

Draft Guidance for Industry, November 2021

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products

Draft Guidance for Industry, December 2021

Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products

Guidance for Industry, September 2022

Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products

Draft Guidance for Industry, February 2023

RWD Source

Submissions

Design



RWD and RWE for Regulatory Purposes

Effectiveness and/or Safety of a New Molecular Entity or Unapproved Product

Labeling Change(s) for an Approved Product

Postmarketing Requirement(s)/ Postmarketing Commitments(s)

Contextual Evidence (Natural History, Utilization, Patterns, or Trends)

For all study designs, it is important to ensure data **reliability** and **relevance**

Reliability

includes data **accuracy**, **completeness**, provenance, and **traceability**

Relevance

includes the availability of key **data elements** (exposure, outcomes, covariates) and sufficient number(s) of representative patients

Alpelisib

Accelerated approval on 4/5/2022 for PIK3CA-Related Overgrowth Spectrum (PROS)



Indication: Treatment of patients ≥ 2 years of age with severe manifestations of PROS who require systemic therapy

Alternative Design Rationale

- Unfeasible to do clinical trial

Rare Disease

- Prevalence ~14 people per million

High Unmet Medical Need

- No approved therapies

Predefined Plans

- Study Objectives and Endpoints, SAP, Enrollment Guidance for EAP

Objective Outcome Validation

- Images available with Blinded Independent Central Review, durable response, ClinRo

Provide substantial evidence of effectiveness and a positive risk: benefit assessment


Use of RWD for Regulatory Purposes

Predefine




All essential elements of study
(design, analysis, conduct)

Describe



How each element was ascertained
from selected RWD source(s)

Address




Issues essential to determining reliability and relevance
of the data in the protocol (including ability for auditing)

Consult




Confer with FDA prior to start of study
Target population, linkages, exposure, covariate, outcome
ascertainment & validation

Current State



Complex and Restrictive



Resource Intensive




Highly Burdensome

- Patients
- Providers

Future State



More streamlined and generalizable



Targeted Objective-focused Approaches




Closer to Routine Care

- Increased Access
- Appropriate Flexibilities

OCE Project Pragmatics

Objective

Advancing evidence generation for approved oncology medical products by exploring innovative trial design approaches that introduce functional efficiencies and patient centricity through integration with real-world routine clinical practice.




Enhancing Generalizability

Clinical Trials



Real World US Population





Possibilities



Challenges

Oncology RWD



Possibilities



Rapid Characterization of Emergent Public Health Needs



Innovative Prospective Designs



rwResponse Data Ascertainment and Validation



Understanding Drug Effects in Underrepresented Populations



Challenges (and Progress)



Source Data and Quality



Causal Inference in Noninterventional Studies



Availability and Analysis of Raw Imaging Data



Oncology QCARD

Oncology Quality, Characterization, and Assessment of Real-World Data



Background: Oncology review divisions receive a high volume of RWD containing submissions in a non-standardized format

Issue: Initial RWD submissions provide insufficient information to allow for substantive review and evaluation with continuous need for clarification (e.g., consistent gaps, repeated sponsor questions)

Objective: Provide structure that can support the inclusion of sufficient information for initial characterization of oncology RWD submissions

Benefit: Increasing efficiencies and facilitating more effective communication

OCE Scientific Collaborative

> Clin Cancer Res. 2021 Oct 1;27(19):5161-5167. doi: 10.1158/1078-0432.CCR-20-4429.

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Julie A Schneider¹, Yutao Gong¹, Kirsten B Goldberg¹, Paul G Kluetz^{1 2}, Marc R Theoret^{1 2}, Laleh Amiri-Kordestani², Julia A Beaver^{1 2}, Lola Fashoyin-Aje^{1 2}, Nicole J Gormley², Adnan A Jaigirdar^{1 3}, Steven J Lemery^{1 2}, Pallavi S Mishra-Kalyani⁴, Gregory H Reaman¹, Donna R Rivera¹, Wendy S Rubinstein^{1 5}, Harpreet Singh^{1 2}, Rajeshwari Sridhara¹, Richard Pazdur^{1 2}

Cell/gene and personalized neo-antigen-based therapies for cancer	Health equity and special populations	Immuno-oncology
Oncology patient-focused drug development	Oncology safety	Oncology trial designs, endpoints and statistical methodologies
Pediatric oncology	Precision oncology	Rare cancers

OCE Projects



Project ASIATICA (ASian americans, nATive hawaiian, and other paCific islAnders) aims to bring focus and awareness to Asian Americans, Native Hawaiians, and Other Pacific Islander (AA & NHOPI) patients with cancer.



Project Catalyst provides guidance and educational resources that help support informed anticancer therapy development to expedite the availability of directed and novel cancer treatments to the public, working primarily with small pharmaceutical companies and academic life science incubators and accelerators.



Project Community is a public health outreach initiative established for patients living with cancer, survivors, advocates, families, and people living in underserved urban and rural communities who are at greater cancer risk.



Project Confirm is an initiative to promote the transparency of outcomes related to accelerated approval for oncology indications



Project Equity is a public health initiative to ensure that the data submitted to the FDA for approval of oncology medical products adequately reflects the demographic representation of patients for whom the medical products are intended.



Project Facilitate is a single point of contact call and information center created to help oncology healthcare providers or regulatory professionals submit an Expanded Access Request for an individual patient with cancer through FDA's Expanded Access Program.




Project FrontRunner aims to encourage drug companies to consider the most appropriate line of treatment setting when developing new cancer therapies, such as in earlier clinical settings.



Project Livin' Label is an educational initiative that aims to foster broad understanding of the associated oncology product label and increase awareness of recent oncology drug FDA approvals in the cancer community.




Project Orbis provides a framework for concurrent submission and review of oncology products among international partners.



Project Optimus is an initiative to reform the dosage optimization and dosage selection paradigm in oncology drug development.



Project Patient Voice is an online platform for patients and caregivers along with their healthcare providers to look at patient-reported symptom data collected from cancer clinical trials.




Project Point/Counterpoint provides a new version of the Oncologic Drugs Advisory Committee (ODAC) briefing document that combines the company's and the FDA's positions in a single document.



Project Pragmatica seeks to introduce functional efficiencies and enhance patient centricity by integrating aspects of clinical trials with real-world routine clinical practice through appropriate use of pragmatic design elements.



Project Renewal is a public health initiative that aims to update the prescribing information (i.e., labeling) for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date



Project SignifiCanT (Statistics in Cancer Trials) promotes collaboration and engagement among diverse stake holders to further the design and analysis of cancer clinical trials with the goal to advance cancer therapies.



Project Silver is a public health initiative to increase representation of older adults (65 years and older) in cancer clinical trials with the goal of improving their treatment, care, and outcome through evidence base data.



Project Socrates provides educational opportunities for hematology/oncology fellows, basic and translational scientists, junior faculty, and others interested in learning more about regulatory science and drug development.

Acknowledgements



Oncology RWE Program



Paul Kluetz
Catherine Lerro
Jennifer Lee
Fatima Rizvi
Richard Curley

OCE Leadership

- Richard Pazdur
- Paul Kluetz
- Marc Theoret
- Tamy Kim

OOD

- Amy Barone
- Diana Bradford
- Elizabeth Duke
- Angelo De Claro
- Martha Donoghue
- Bindu Kanapuru
- Gautam Mehta
- Kelly Norsworthy
- Melanie Royce
- Julie Schneider
- Harpreet Singh
- Sonia Singh
- Joseph Wynne

OB

- Pallavi Mishra-Kalyani
- Jonathon Vallejo

- Office of Medical Policy
- CDER
- CBER
- CDRH



Thank you!

Additional Questions?

Please email OCERWE@fda.hhs.gov



U.S. FOOD & DRUG
ADMINISTRATION